December 13th, 2017
FOR 5:00 PM RELEASE
TSX-V: TBP

Tetra Bio-Pharma Reinforces its Development Program by Signing Research & Development Agreement with Constance Therapeutics and Receiving Financial Support from NSERC

Ottawa, Ontario - (Marketwired – December 13th, 2017) – Tetra Bio-Pharma Inc. ("**Tetra**" or the "**Company**") (TSX-V: TBP) (OTCQB: TBPMF), a global leader in cannabinoid-based drug development and discovery, is pleased to announce that the company has signed an exclusive research and development (R&D) agreement with Constance Therapeutics for the pharmaceutical drug development, and eventual commercialization in Canada, of their standardized, patent-pending, medicinal cannabis extract products. In addition to this agreement, the Company further strengthens its R&D program by means of a National Sciences and Engineering Research Council of Canada (NSERC) grant in its collaborative project with Dr Stan Kubow at McGill university.

Constance Therapeutics has developed whole plant cannabis extracts that have shown significant clinical promise in the treatment of various forms of cancer and improved patient survival as well. In collaboration, Tetra and Constance Therapeutics now aim to define the therapeutic mechanism and demonstrate efficacy of these cannabis extracts in the treatment of human cancers. In accordance with Tetra's provisional patent announced on May 17th, 2017, the collaboration will focus on treating various forms of cancer driven by inappropriate Hedgehog signaling, including multiple forms of brain, blood, skin and bone cancers.

Constance Finley, Founder and CEO of Constance Therapeutics, Inc. said, "over the years, research has demonstrated that cannabinoids including specific terpenes, reduce and inhibit tumor growth in various animal models. Early clinical studies suggest cannabinoids enhance the effects of traditional cancer treatments with radiation therapy and help reduce the size of brain cancers, such as Glioma, compared to controls."

"We are very excited to achieve this co-development program with Constance Therapeutics" added Bernard Fortier, CEO of Tetra. "Their initial research is very promising and we are hopeful that together we can provide novel treatments for multiple forms of aggressive cancer to patients with limited therapeutic options. "

In addition, Tetra is pleased to announce that the company has been awarded an additional Engage Plus grant from the National Sciences and Engineering Research Council of Canada (NSERC) to continue the collaborative project with Dr. Stan Kubow of McGill University. The goal of the basic research project is to explore and develop patentable cannabis-derived retail supplements and drug products in partnership with McGill University, and the grant awarded by NSERC will bolster Tetra Bio-Pharma’s investment with matching funds up to a maximum of $12,500.

“We are excited and honored to have the continued support of NSERC on this innovative project with McGill. Through the use of Dr. Kubow’s expertise and access to the advanced facility at McGill University, we aim to develop novel natural health supplements and drug products to be commercialized by Tetra,” commented Dr. Guy Chamberland, Chief Scientific Officer or Tetra Bio-Pharma.

Together, the co-development project focused on treating Hh-driven disease and the continuation of the McGill collaboration aiming to develop new cannabis-based products diversifies and strengthens Tetra’s pre-clinical program, thus ensuring the continuity of the product pipe-line in the future.

Lassen U, Mau-Sørensen M, Poulsen HS Orphan drugs in glioblastoma multiforme: a review Orphan Drugs: Research and Reviews 2014:4; 83-91

About Constance Therapeutics:
Constance Therapeutics, Inc. is a manufacturer and licensor of cannabis products designed to enable medical professionals to offer their patients a broader array of treatment options. The products fill the gap between traditional pharmaceuticals and commonplace cannabis products through manufacturing protocols using highly controlled, quantitatively-defined and patented processes. The products are third-party tested in the industry's most respected laboratories. Since 2008, the company has employed stringent, science-based processes and standards to ensure the highest quality and consistency. Headquartered in San Francisco, California, Constance Therapeutics' products have historically been accessed exclusively for therapeutic use and could only be purchased by registered California patients, in keeping with Proposition 215, and California Senate Bill 420.
More information at: www.constancetherapeutics.com

About Dr. Stan Kubow:
Dr. S. Kubow, Ph.D. is an Associate Professor at the School of Dietetics and Human Nutrition, McGill University. His research interests include the impact of nutritional interventions on a variety of disease outcomes and metabolic disorders using technologically modified food extracts and isolates with enhanced bioactivity including phytochemical extracts, whey and soy proteins and probiotics. These studies have been focused upon oxidative stress, inflammatory indices, lipoprotein, fatty acid and glucose metabolism as related to cell signaling pathways and disease pathogenesis.

About Tetra Bio-Pharma:
Tetra Bio-Pharma (TSX-V: TBP) (OTCQB: TBPMF) is a biopharmaceutical leader in cannabinoid-based drug discovery and clinical development. Tetra is focusing on three core business pillars: clinical research, pharmaceutical promotion and retail commercialization of cannabinoid-based products.

More information at: www.tetrabiopharma.com
Source: Tetra Bio-Pharma

For further information, please contact Tetra Bio-Pharma Inc.
Dr. Anne-Sophie Courtois, DVM
Vice President, Marketing & Communications
anne-sophie.courtois@tetrabiopharma.com
(514) 360-8040 Ext. 210

Forward-looking statements

Some statements in this release may contain forward-looking information. All statements, other than of historical fact, that address activities, events or developments that the Company believes, expects or anticipates will or may occur in the future (including, without limitation, statements regarding potential acquisitions and financings) are forward-looking statements. Forward-looking statements are generally identifiable by use of the words "may", "will", "should", "continue", "expect", "anticipate", "estimate", "believe", "intend", "plan" or "project" or the negative of these words or other variations on these words or comparable terminology. Forward-looking statements are subject to a number of risks and uncertainties, many of which are beyond the Company's ability to control or predict, that may cause the actual results of the Company to differ materially from those discussed in the forward-looking statements. Factors that could cause actual results or events to differ materially from current expectations include, among other things, without limitation, the inability of the Company, through its wholly-owned subsidiary, GrowPros MMP Inc., to obtain a license for the production of medical marijuana; failure to obtain sufficient financing to execute the Company's business plan; competition; regulation and anticipated and unanticipated costs and delays, the success of the Company's research strategies, the applicability of the discoveries made therein, the successful and timely completion and uncertainties related to the regulatory process, the timing of clinical trials, the timing and outcomes of regulatory or intellectual property decisions and other risks disclosed in the Company's public disclosure record on file with the relevant securities regulatory authorities. Although the Company has attempted to identify important factors that could cause actual results or events to differ materially from those described in forward-looking statements, there may be other factors that cause results or events not to be as anticipated, estimated or intended. Readers should not place undue reliance on forward-looking statements. The forward-looking statements included in this news release are made as of the date of this news release and the Company does not undertake an obligation to publicly update such forward-looking statements to reflect new information, subsequent events or otherwise unless required by applicable securities legislation.